ASH Annual Meeting
from OT Broadcast News
Peter Goodwin talks to key investigators Francesco Zaja (on rituximab for ITP); Hannes Wandt (on how platelet transfusions may be able to be withheld in certain patients receiving stem cell transplants for hematologic cancers); and Michael Hallek and Tadeusz Robak (on improved benefits for CLL patients with rituximab added to standard chemotherapy). Offering perspective are Kenneth Kaushansky, Linda Burns, and George Canellos.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OT Broadcast News?
This episode is 26 minutes long.
When was this OT Broadcast News episode published?
This episode was published on January 20, 2009.
Can I download this OT Broadcast News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.